What guidance did Maravai's management provide for the next earnings period?

What is the market's earnings forecast for Maravai next quarter?

What factors drove the changes in Maravai's revenue and profit?

Did Maravai beat or miss consensus estimates last quarter?

What is Maravai's latest dividend and current dividend yield?

What is Maravai's gross profit margin?

What were the key takeaways from Maravai's earnings call?

What is the revenue and EPS growth rate for Maravai year over year?

- **Revenue recovery**: Q4 2025 revenue (ex-COVID) up 18% YoY, with 2026 guidance of $200-210M (+8-13% YoY).
- **Profitability turnaround**: Q4 2025 EBITDA positive after 4 quarters of losses, with 2026 EBITDA guidance of $18-20M.
- **Gross margin expansion**: 1,200bps improvement expected in 2026, driven by restructuring and GMP product mix.
- **Strategic momentum**: ModTail technology generating $0.5M+ in 2025, and >$1.2M in GMP enzyme orders booked for 2026.
- **Operational efficiency**: $65M+ annualized cost savings achieved, with 13%+ OpEx decline in 2026.

**【CEO Summary Section】**
- Full year 2025 revenue of $185.7 million exceeded guidance by $700,000. Q4 revenue (excluding $14.3M COVID-related sales) grew 18% YoY, driven by TriLink's GMP consumables and Cygnus' core protein kits.
- Achieved positive adjusted EBITDA of $500K in Q4, up $11M sequentially, marking the first return to positive EBITDA in 4 quarters.
- 2026 guidance: $200-210M revenue (+8-13% YoY), $18-20M adjusted EBITDA, and 1,200bps gross margin expansion.
- Strategic focus on customer engagement, operational efficiency, and new product launches (e.g., GMP enzymes, ModTail technology).

**【CFO Financial Commentary】**
- Q4 2025 GAAP net loss: $63M (incl. $25.8M asset impairment). Full year GAAP loss: $230.8M vs. $259.6M in 2024.
- 2025 cost savings exceeded $50M target, with $65M+ annualized savings now expected. Operating expenses to decline 13% in 2026.
- 2026 financial metrics: 13%+ revenue growth, 1,200bps gross margin expansion, and $18-20M EBITDA.

**【Q&A Key Highlights】**
- **Order visibility**: Q1 2026 orders already exceed Q1 2025 levels, with strong demand in GMP consumables and discovery tools.
- **GMP growth drivers**: >$1.2M in GMP enzyme orders booked for 2026, and ModTail technology generating $0.5M+ in 2025 revenue.
- **AI adoption**: mRNAbuilder platform processed 70+ orders, enabling seamless transition from discovery to GMP supply.
- **Cygnus expansion**: MockV product line growth and mass spec infrastructure expansion to drive analytical services revenue.
- **Cost structure**: 2026 G&A expenses to decline 18%, with R&D modestly up to support NPI pipeline.


Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

- **Q3 Growth Drivers**: BST up 7% YoY, NAP down 53% YoY due to GMP order timing. 
- **Cost Savings**: $50+ million annualized reductions, $7M Q4 EBITDA improvement. 
- **Innovation Impact**: ModTail adoption by 9 clients, IVT kits seeing strong early bookings. 
- **2026 Outlook**: Positive EBITDA target, $10-20M COVID-related GMP revenue. 
- **Liquidity Strength**: $243.6M cash, disciplined expense management.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Total revenue of $41.6 million, with Biologics Safety Testing (BST) growing 7% YoY to $16.3 million and Nucleic Acid Products (NAP) declining 53% YoY to $25.4 million. 
- **Restructuring Progress**: Over $50 million annualized expense reduction, with $7 million sequential EBITDA improvement expected in Q4. 
- **Innovation Highlights**: Launch of ModTail mRNA technology (already adopted by 9 clients) and IVT kits, driving cross-product adoption. 
- **2026 Outlook**: Targeting positive adjusted EBITDA, with $10-20 million annualized COVID-related GMP CleanCap revenue.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP net loss of $45.8 million, adjusted EBITDA loss of $10.8 million. 
- **Cost Structure**: $50+ million expense reduction (40-50% from labor, 15-20% from facilities), split 50-50 between COGS and OpEx. 
- **2025 Guidance**: Revenue of ~$185 million, with Q4 growth of 18% YoY and base business (excluding COVID) up 16% YoY. 
- **Liquidity**: $243.6 million cash, $295.6 million long-term debt.

**【Q&A Key Highlights】**
- **Order Visibility**: Strong Q4 GMP consumables bookings, with multiyear CDMO contracts. 
- **ModTail Adoption**: 9 clients using mRNA + ModTail services, 14 ordering catalog products. 
- **Funding Environment**: Discovery revenue down due to macro conditions, but stability in higher-value orders. 
- **China Recovery**: BST growth in U.S. and Europe offset China decline, with hope for normalization in 2026. 
- **Platform Efficiency**: mRNA Builder platform doubles order conversion rate, reducing direct engagement needs.

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2025 Earnings Call Transcript

- **$50M Cost Reduction Plan**: Annualized savings targeting 2026 profitability, with $8-9M restructuring charges in 2025H2.
- **BST Segment Strength**: 10% YoY revenue growth (to $16.3M) with 67% EBITDA margin, driven by viral clearance innovation.
- **GMP Expansion**: Investing in mRNA therapeutics for oncology and rare diseases, positioning for long-term growth.
- **2026 Profit Target**: Positive adjusted EBITDA and free cash flow, independent of high-volume CleanCap orders.
- **E-Commerce Initiative**: Launching mRNAbuilder to capture research market share, targeting mid-single-digit base growth.

**【CEO Summary Section】**
- **New Leadership Vision**: CEO Bernd Brust emphasized restructuring to reduce annualized costs by over $50 million, transitioning to a streamlined functional model to improve decision-making and accountability.
- **3-Part Strategic Plan**: 
  1. **Operational Excellence**: Phased restructuring to complete within 12 months, focusing on headcount and non-headcount expense reductions.
  2. **Growth Levers**: Diversifying revenue through Biologics Safety Testing (BST) innovation and expanding GMP capabilities for mRNA therapeutics.
  3. **Profitability Target**: Aiming for positive adjusted EBITDA and free cash flow by H2 2026.
- **BST Segment Highlight**: The BST business (Cygnus) achieved 10% YoY revenue growth, driven by Host Cell Protein kits and MockV viral clearance products, with a 67% EBITDA margin.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: 
  - Total revenue: $47.4 million (down 32% YoY), with base NAP revenue up 5% YoY excluding high-volume CleanCap.
  - GAAP net loss: $69.1 million; adjusted EBITDA: -$10.4 million (vs. +$13 million YoY).
  - Cash balance: $270 million; long-term debt: $297 million.
- **Cost Reduction Initiatives**: 
  - $50+ million annualized savings: 45-50% from labor, 15-20% from facilities, 15-20% from CapEx, and 15-20% from productivity improvements.
  - Restructuring charges: $8-9 million in H2 2025.
- **Segment Performance**: 
  - NAP: Revenue $31.1 million, EBITDA -$7.3 million (down 14% YoY).
  - BST: Revenue $16.3 million, EBITDA $10.9 million (up 10% YoY).

**【Q&A Highlights】**
- **Guidance Philosophy**: Withdrew prior guidance due to ongoing business review; expects to reinstate in Q3 2025.
- **BST Growth**: 10% YoY growth driven by MockV adoption and qualification services; no material pull-forward dynamics from China.
- **China Expansion**: Potential growth driver post-U.S.-China easing, particularly in BST.
- **E-Commerce Strategy**: Launching mRNAbuilder tool to streamline custom mRNA ordering, targeting mid-single-digit base growth.
- **2026 Outlook**: Confident in achieving positive EBITDA and free cash flow without relying on high-volume CleanCap orders.


Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2025 Earnings Call Transcript

- **Q1 Revenue Beat**: $47 million (+$4M sequential growth), driven by NAP (+$1M) and BST (+$3M). Base business excludes high-volume CleanCap.
- **Tariff Resilience**: 100% U.S. manufacturing mitigates risks; China BST Q1 revenue $3.8M (21% of BST) but outlook flat for 2025.
- **Innovation Momentum**: Launches include Poly(A+) mRNA tail modifications and high-fidelity CRISPR guides. 5 new CleanCap agreements bring total to 48.
- **Pipeline Growth**: 14 programs advanced to clinical in Q1, 35% of tracked programs use CleanCap.
- **Financial Outlook**: Full year revenue $185-$205M, Q2 $45-$50M, H2 $100M midpoint. Cash position $285M supports reset period.
- **Long-Term Strategy**: Vertical integration reduces COGS; Officinae AI/ML DOE services drive process efficiency.


**【CEO Summary Section】**
- Q1 2025 revenue of $47 million exceeded expectations, with base business growth of $4 million from Q4 2024. NAP segment revenue was $29 million, up $1 million from Q4, while BST revenue was $18 million, up $3 million from Q4.
- Tariff mitigation efforts include 100% U.S.-based manufacturing for TriLink, Cygnus, and AlphaZyme, with minimal impact on supply chain to date. China BST revenue of $3.8 million (21% of BST) was mitigated for H1, but risks remain for H2.
- Key innovations launched include Poly(A+) tail modifications for mRNA stability and high-fidelity HPLC-purified CRISPR guides. 5 new CleanCap license/supply agreements were signed, bringing total to 48.
- GMP pipeline progress: 95 new preclinical programs added in Q1, 14 advanced to clinical, and 91 discontinued. CleanCap customers represent 35% of tracked programs.

**【CFO Financial Commentary】**
- Q1 GAAP net loss: $53 million (vs. $23 million in Q1 2024). Adjusted EBITDA: -$11 million (vs. +$8 million in Q1 2024). Adjusted EPS: -$0.08 (in line with expectations).
- Cash position: $285 million. Full year revenue guidance reaffirmed at $185-$205 million. Q2 revenue expected $45-$50 million, with H2 at $100 million midpoint.
- Cost structure: ~$200 million annual fixed costs. Breakeven revenue ~$225 million annually. Q1 R&D and SG&A: $14 million (down $2 million YoY).

**【Q&A Key Themes】**
- **Tariff Mitigation**: 100% U.S. manufacturing mitigates direct risks. China BST distributor orders strong in Q1 ($3.8 million), but outlook flat for 2025. No direct tariff costs incurred to date.
- **BST Seasonality**: Q1 is peak for biologics safety testing, with Q2/Q3 typically lower. Q1 BST revenue of $18 million was highest since Q1 2024.
- **Academic Funding**: 4% of revenue from academia, with mixed funding outlook. Customers report securing 10-year grants but delays due to policy uncertainty.
- **Flanders Facility**: GMP mRNA production ramping up, with visibility into 2H 2025 orders. Cross-selling opportunities with enzyme and reagent products.
- **Long-Term Growth**: Vertical integration (MyChem, AlphaZyme, Molecular Assemblies) reduces COGS and enables mRNA cost reduction. Officinae Bio's AI/ML DOE optimization services see early adoption in process development.


Maravai LifeSciences (MRVI)-12 May 25-2025 Q1 Earnings call transcript

- **Revenue Stability**: 2024 base business of $193 million, with 2025 guidance of $185-$205 million. Excludes high-volume CleanCap, reflecting cautious market outlook.
- **Profitability Focus**: Adjusted EBITDA margin of 14% in 2024, targeting leverage from fixed cost structure ($200 million) as revenue grows. Variable costs at 10-12% of revenue.
- **Growth Drivers**: New Flanders facilities support GMP expansion. 50+ new products launched in 2024, including CleanScribe and MOC-V, targeting mRNA and viral clearance markets.
- **Market Visibility**: Clinical trial tracking platform monitors 1,500 programs. 30% of BST customers disclose IND/BLA milestones, improving forecasting accuracy.
- **Financial Health**: $322 million cash, $22 million net cash position. 2025 CapEx decline to $15 million, supporting margin expansion.


**【CFO Financial Overview】**
- **Q4 2024 Financials**: Total revenue of $57 million, with full-year revenue of $259 million (midpoint of guidance). Adjusted EBITDA was -$1 million for Q4 and $36 million for the year (14% margin). GAAP net loss was $46 million for Q4 and $260 million for the year.
- **Segment Performance**: Nucleic Acid Production (NAP) segment revenue of $196 million (adjusted EBITDA $51 million, 26% margin). Biologics Safety Testing (BST) segment revenue of $63 million (adjusted EBITDA $44 million, 70% margin).
- **2025 Guidance**: Base business revenue of $185-$205 million (excluding high-volume CleanCap). Capital expenditures expected to decline to $15 million. Interest expense projected at $14-$16 million, depreciation/amortization at $50-$55 million.
- **Liquidity**: $322 million in cash, $300 million in long-term debt, resulting in a $22 million net cash position.

**【CEO Strategic Initiatives】**
- **Capacity Expansion**: New Flanders 1 and 2 facilities operational, supporting GMP chemistry and mRNA production. Recent customer commitment extends support from Phase II/III to commercial launch.
- **Product Innovation**: 50 new products launched in 2024, including CleanScribe enzyme and MOC-V viral clearance kits. Acquisitions of Officinae Bio and Molecular Assemblies to enhance DNA/RNA design capabilities.
- **Market Penetration**: 43 license agreements for CleanCap, with 3 customers reporting IND/BLA milestones in Q4. Biologics Safety Testing (BST) segment sees 70% of programs in preclinical stages, targeting cancer (38% of pipeline).
- **Cost Management**: Corporate shared services expenses reduced by 10% to $59 million for the year. Focus on variable margin contribution as business returns to growth.

**【Q&A Highlights】**
- **Profitability Levers**: Gross margin variability tied to revenue mix and manufacturing variances. Fixed cost structure of ~$200 million for 2025, with variable costs at 10-12% of revenue.
- **Visibility Improvements**: Clinical trial business intelligence platform tracks 1,500 mRNA/gene editing programs. License agreements require disclosure of IND/BLA milestones, enhancing forecasting accuracy.
- **China Growth**: Flat guidance for 2025, with BST revenue of $13.6 million in 2024. Shifting CDMO activity from China to APAC offsets regional volatility.
- **Debt Management**: $228 million voluntary debt repayment in Q4 2024 reduces 2025 interest expense. No immediate M&A plans, but open to small, strategic acquisitions.


Actual	0.2146	0.26	0.44	0.44	0.45	0.54	0.54	0.37	0.35	0.03	0	-0.01	0.01	-0.02	0	-0.02	-0.06	-0.08	-0.08	-0.08	-0.04
Forecast	0.1065	0.2103	0.3157	0.3517	0.3847	0.4388	0.454	0.3297	0.3413	0.032	0.0127	0.0056	-0.0115	-0.0261	0.001	-0.0084	-0.0397	-0.0707	-0.0738	-0.0821	-0.0702
Surprise	+101.50%	+23.63%	+39.37%	+25.11%	+16.97%	+23.06%	+18.94%	+12.22%	+2.55%	-6.25%	-100.00%	-278.57%	+186.96%	+23.37%	-100.00%	-138.10%	-51.13%	-13.15%	-8.40%	+2.56%	+43.02%

MRVI

MRVI fundamentals

MRVI Q4 2025 Earnings

Earnings Call

You can ask Aime

MRVI

MRVI fundamentals

MRVI Q4 2025 Earnings

Earnings Call

MRVI Earnings Call Summary for Q4/20255:00 PM on Feb 25, 2026

MRVI Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

MRVI Earnings Call Summary for Q2/20255:00 PM on Aug 11, 2025

MRVI Earnings Call Summary for Q1/20255:00 PM on May 12, 2025

MRVI Earnings Call Summary for Q4/20245:00 PM on Mar 20, 2025

You can ask Aime